Catalog No.
DHJ92701
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Ig epsilon chain C region, IGHE, Ig epsilon chain C region ND, Immunoglobulin heavy constant epsilon
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01854
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IGE25, olizumab, pSVIE26, rhuMab-E25, CAS: 242138-07-4,MaE11
Clone ID
Omalizumab
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials, PMID: 32524991
Roles of omalizumab in various allergic diseases, PMID: 32067933
The use of omalizumab in allergen immunotherapy, PMID: 29315922
Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence, PMID: 32418171
Omalizumab in the Treatment of Chronic Inducible Urticaria, PMID: 27717421
From IgE to Omalizumab, PMID: 27864548
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness, PMID: 30400762
Off-Label Uses of Omalizumab, PMID: 26048266
Omalizumab for atopic dermatitis: evidence for and against its use, PMID: 30717578
Omalizumab for Severe Asthma: Beyond Allergic Asthma, PMID: 30310816
Omalizumab for chronic urticaria in children younger than 12 years, PMID: 31082483
Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence, PMID: 30427977
Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature, PMID: 28226418
Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review, PMID: 28631599
Efficacy and effectiveness of omalizumab in the treatment of childhood asthma, PMID: 30141696
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma, PMID: 31049972
Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience, PMID: 28477722
Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma, PMID: 31760132
Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence, PMID: 28751232
Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature, PMID: 30421306
The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors, PMID: 31770111
Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature, PMID: 32358910
How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers, PMID: 31374358
Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, PMID: 32401603
Pediatric use of omalizumab for allergic asthma, PMID: 32241196
Omalizumab in severe eczema, PMID: 32725741
Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver?, PMID: 31764954
Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan, PMID: 30053973
[Omalizumab: Beyond anti-IgE properties], PMID: 28189435
Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence, PMID: 32108461
Should omalizumab be used in severe asthma/COPD overlap?, PMID: 30043557
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria, PMID: 29132956
Novel targets of omalizumab in asthma, PMID: 27798419
Role of Biologics in Asthma, PMID: 30525902
Omalizumab re-treatment rates in chronic spontaneous urticaria, PMID: 32378397
Omalizumab: living up to PROMises, PMID: 30604545
The discovery and development of omalizumab for the treatment of asthma, PMID: 25979110
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018, PMID: 30763137
New insights into the utility of omalizumab, PMID: 30690050
A review of omalizumab for the management of severe asthma, PMID: 27528798
Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization, PMID: 32561499
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?, PMID: 31779657
Omalizumab and Mast Cell Disorders: Are We There Yet?, PMID: 31495435
The Use of Omalizumab in Food Oral Immunotherapy, PMID: 27628022
Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab, PMID: 30107875
Response of omalizumab in normocomplementemic urticarial vasculitis, PMID: 32145404
Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety, PMID: 32467066
Omalizumab concentrations in pregnancy and lactation: A case study, PMID: 32544544
Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic, PMID: 29744661
Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis, PMID: 33160644
For research use only. Not for human or drug use.
